PE20221894A1 - Agentes de union a ilt y metodos para su uso - Google Patents

Agentes de union a ilt y metodos para su uso

Info

Publication number
PE20221894A1
PE20221894A1 PE2022002422A PE2022002422A PE20221894A1 PE 20221894 A1 PE20221894 A1 PE 20221894A1 PE 2022002422 A PE2022002422 A PE 2022002422A PE 2022002422 A PE2022002422 A PE 2022002422A PE 20221894 A1 PE20221894 A1 PE 20221894A1
Authority
PE
Peru
Prior art keywords
binding agents
methods
ilt
ilt2
ilt4
Prior art date
Application number
PE2022002422A
Other languages
English (en)
Spanish (es)
Inventor
Dana Yen Mei Duey
Jr Allen James Ebens
Daniel David Kaplan
Chia-Ying Kao Lam
Kalyani Mondal
Geoffrey William Stone
Yan Wang
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of PE20221894A1 publication Critical patent/PE20221894A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2022002422A 2020-05-01 2021-04-29 Agentes de union a ilt y metodos para su uso PE20221894A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019068P 2020-05-01 2020-05-01
US202063122848P 2020-12-08 2020-12-08
PCT/US2021/029866 WO2021222544A1 (en) 2020-05-01 2021-04-29 Ilt-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20221894A1 true PE20221894A1 (es) 2022-12-13

Family

ID=76012027

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002422A PE20221894A1 (es) 2020-05-01 2021-04-29 Agentes de union a ilt y metodos para su uso

Country Status (17)

Country Link
US (3) US11802155B2 (enExample)
EP (2) EP4143229B1 (enExample)
JP (2) JP7834028B2 (enExample)
KR (1) KR20230005978A (enExample)
CN (2) CN116589581A (enExample)
AU (2) AU2021265801B2 (enExample)
BR (1) BR112022021684A2 (enExample)
CA (1) CA3181197A1 (enExample)
CL (1) CL2022003004A1 (enExample)
CO (1) CO2022015208A2 (enExample)
ES (1) ES3039441T3 (enExample)
IL (1) IL297748A (enExample)
MX (1) MX2022013466A (enExample)
MY (1) MY209480A (enExample)
PE (1) PE20221894A1 (enExample)
TW (1) TW202206463A (enExample)
WO (1) WO2021222544A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
CN119156229A (zh) * 2022-03-04 2024-12-17 D2M生物治疗有限公司 抗lilrb1/2抗体及其用途
AU2023231622A1 (en) * 2022-03-07 2024-09-26 Agenus Inc. Anti-ilt2 antibodies and uses thereof
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
WO2023235703A1 (en) * 2022-05-31 2023-12-07 Ngm Biopharmaceuticals, Inc. Therapeutic methods using ilt-binding agents
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望（蘇州）生物醫藥科技有限公司 抗lilrb2抗體及其用途
EP4628508A1 (en) * 2022-12-09 2025-10-08 Biodlink Biopharm Co., Ltd. Anti-ilt4 antibody as well as preparation method therefor and use thereof
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4637924A2 (en) * 2022-12-23 2025-10-29 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024218650A1 (en) * 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2025059304A2 (en) * 2023-09-12 2025-03-20 Agenus Inc. Methods of treating cancer using ilt2 antibodies and combination therapies
GB202314087D0 (en) * 2023-09-14 2023-11-01 Macomics Ltd Biomarker for cancer
WO2025168070A1 (zh) * 2024-02-08 2025-08-14 东曜药业有限公司 一种抗ilt2/4单抗的制剂、包含其的药盒及其应用
WO2025191142A2 (en) 2024-03-15 2025-09-18 Les Laboratoires Servier Antibodies to lilrb1 and lilrb2 and compositions thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948623B1 (en) 1996-12-06 2010-01-27 Schering Corporation Isolated mammalian monocyte cell genes; related reagents
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
AU2002360376B2 (en) 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
EP1981522B1 (en) 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
KR20090082480A (ko) 2006-11-14 2009-07-30 제넨테크, 인크. 뉴런 재생의 조절인자
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
KR20100109923A (ko) 2007-12-11 2010-10-11 제넨테크, 인크. 뉴런 재생의 조정인자
AU2009246443A1 (en) 2008-05-13 2009-11-19 Genentech, Inc. Anti-PirB antibodies
US20090285803A1 (en) 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP2970373A1 (en) 2013-03-12 2016-01-20 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
WO2015179633A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
US20170274003A1 (en) 2014-09-16 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3256163A4 (en) 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CA3218106A1 (en) 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
EP3344263A4 (en) 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIGEN TARGETS AND USES THEREOF
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
JP7194481B2 (ja) 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
JPWO2019107387A1 (ja) 2017-11-28 2020-12-17 国立大学法人大阪大学 マラリア治療薬、マラリアの治療方法、マラリア治療用候補物質のスクリーニング方法、マラリア重症化マーカー、マラリアの重症化の危険度を試験する方法および試験試薬
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
EP3740224A4 (en) 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020023268A1 (en) * 2018-07-24 2020-01-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
NZ789331A (en) 2019-12-19 2026-02-27 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
WO2021133036A1 (ko) 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도

Also Published As

Publication number Publication date
US20210355211A1 (en) 2021-11-18
ES3039441T3 (en) 2025-10-21
US11802155B2 (en) 2023-10-31
BR112022021684A2 (pt) 2023-01-17
EP4143229B1 (en) 2025-07-30
IL297748A (en) 2022-12-01
JP2026116918A (ja) 2026-07-14
TW202206463A (zh) 2022-02-16
CO2022015208A2 (es) 2023-01-16
WO2021222544A1 (en) 2021-11-04
AU2026204926A1 (en) 2026-07-16
MY209480A (en) 2025-07-11
JP2023523628A (ja) 2023-06-06
CA3181197A1 (en) 2021-11-04
AU2021265801B2 (en) 2026-04-02
US20260226164A1 (en) 2026-08-06
CL2022003004A1 (es) 2023-06-23
US20240025997A1 (en) 2024-01-25
EP4143229A1 (en) 2023-03-08
EP4691561A2 (en) 2026-02-11
AU2021265801A1 (en) 2022-11-17
US12410251B2 (en) 2025-09-09
KR20230005978A (ko) 2023-01-10
MX2022013466A (es) 2022-11-16
JP7834028B2 (ja) 2026-03-23
CN116589581A (zh) 2023-08-15
CN115768524A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
PY1888702A (es) Anticuerpos anti-cd38 y métodos de uso
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
MX2020010946A (es) Anticuerpos multiespecificos y usos del mismo.
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
MX2013013832A (es) Proteínas de unión receptoras fc.
CO6721052A2 (es) Anticuerpos para e receptor de la barrera hematoencefálica de baja afinidad y sus usos
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
CO2020013468A2 (es) Agentes de unión a c3 y métodos para su uso
MX2024011781A (es) Agentes de union a ilt3 y cd3 y metodos de uso de estos
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
AR121974A1 (es) Agentes de unión a ilt y métodos para su uso
AR122678A1 (es) Agentes de unión a lair-1 y métodos para su uso